MedElevator Войти в исследования
← Поиск публикаций

DOI 10.64898/2026.09.17.26363341

Медицинская библиотека · medRxiv : the preprint server for health sciences · 2026

Long-Term Efficacy and Allograft Loss after Immune Checkpoint Inhibitor Therapy in Solid Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma.

Wu Hannah, Murphy Molly, Becot Corentin, Fragano Angela M, Lin Ethan H S, Surapaneni Sruthi, Shirvani Daniel, Cimoch Christine, Merkin Ross, Cohen Sonia, Williams Winfred W, Emerick Kevin, Kaufman Howard L, Shalhout Sophia Z

СтатьяПрепринтПеревод в очереди

Аннотация

BACKGROUND

Immune checkpoint inhibitors (ICIs) can provide effective treatment for advanced cutaneous squamous cell carcinoma (CSCC) in solid organ transplant recipients (SOTRs), but long-term oncologic and allograft outcomes remain poorly characterized.

OBJECTIVE

To evaluate long-term efficacy and allograft outcomes after ICI therapy in SOTRs with advanced CSCC.

METHODS

We conducted a retrospective cohort study of SOTRs with advanced CSCC treated with systemic ICI at Mass General Brigham from 2016-2025. Tumor response, survival, immune-related adverse events, immunosuppression modifications, rejection rate, and graft loss were assessed. Kidney graft failure was analyzed using competing-risk methods with death as a competing event.

RESULTS

Among 36 SOTRs, objective response rate was 44.4% (95% CI, 27.9%-61.9%), including 9 complete responses. At 3 years, progression-free, disease-specific, and overall survival were 18.6%, 65.8%, and 32.5%, respectively. Median follow-up was 42.1 months. Five patients experienced graft loss, all kidney recipients; 4 had biopsy-confirmed rejection. The 3-year cumulative incidence of kidney graft failure was 16.7% (95% CI, 2.9%-30.5%).

LIMITATIONS: Retrospective design, modest sample size, and heterogeneous immunosuppression limited risk-factor analyses.

CONCLUSION

ICI provided long-term CSCC control with a low rate of allograft loss, highlighting the need for longitudinal multidisciplinary management balancing oncologic benefit, graft preservation, and competing mortality risk.

Для цитирования: Wu Hannah, Murphy Molly, Becot Corentin, Fragano Angela M, Lin Ethan H S, Surapaneni Sruthi, Shirvani Daniel, Cimoch Christine, Merkin Ross, Cohen Sonia, Williams Winfred W, Emerick Kevin, Kaufman Howard L, Shalhout Sophia Z. Long-Term Efficacy and Allograft Loss after Immune Checkpoint Inhibitor Therapy in Solid Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma.. medRxiv : the preprint server for health sciences. 2026. DOI: 10.64898/2026.09.17.26363341.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.